DACOGEN®, in a phase III trial
DACOGEN® (decitabine) for Injection, a hypomethylating agent indicated to treat
patients with myelodysplastic syndromes (MDS), was proven superior to supportive
care in treating patients with MDS, demonstrating a better overall improvement
rate, durable responses (41 weeks), transfusion independence in all responders, and more.1
IMPORTANT SAFETY INFORMATION
DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing
potential should be advised to avoid becoming pregnant while using DACOGEN. Men
should be advised not to father a child while receiving treatment with DACOGEN,
and for 2 months afterwards. The most commonly occurring adverse reactions include
neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae,
constipation, diarrhea, and hyperglycemia.
DACOGEN is available by prescription only. Please see the important product information
for DACOGEN for more information. This site does not contain everything that is
known about DACOGEN. If you would like to know more, talk to your healthcare professional.
This Web site contains information relating to various medical conditions and their
treatment. Such information is provided for educational purposes only and is not
meant to be a substitute for the advice of a physician or other health care professional.
You should not use this information for diagnosing a health problem or disease.
Individual responses to DACOGEN treatment may vary.
This site is intended for health care professionals in the United States only. The
products discussed herein may have different product labeling in different countries.
All information collected in this Web site is held in strictest confidence and will
only be used for purposes as specified and will not be sold or distributed to other
parties.